标准方案和替代方案中 CFTR 调节剂的药代动力学变异性。

IF 3.3 3区 医学 Q2 PHARMACOLOGY & PHARMACY
Natalie R. Rose, Ashritha R. Chalamalla, Bryan A. Garcia, Stefanie Krick, Jonathan Bergeron, Hossein Sadeghi, Dennis E. Schellhase, Kevin J. Ryan, Alexander E. Dowell, Edward P. Acosta, Jennifer S. Guimbellot
{"title":"标准方案和替代方案中 CFTR 调节剂的药代动力学变异性。","authors":"Natalie R. Rose,&nbsp;Ashritha R. Chalamalla,&nbsp;Bryan A. Garcia,&nbsp;Stefanie Krick,&nbsp;Jonathan Bergeron,&nbsp;Hossein Sadeghi,&nbsp;Dennis E. Schellhase,&nbsp;Kevin J. Ryan,&nbsp;Alexander E. Dowell,&nbsp;Edward P. Acosta,&nbsp;Jennifer S. Guimbellot","doi":"10.1016/j.pupt.2024.102301","DOIUrl":null,"url":null,"abstract":"<div><p>Elexacaftor, tezacaftor, ivacaftor (ETI) is a CFTR modulator combination approved for use in ∼90 % of people with cystic fibrosis (pwCF) over 2 years old. While most pwCF tolerate this therapy well, some are intolerant to standard dosing, and others show little response. Clinical providers may adjust ETI dosing to combat these issues, but these adjustments are not well guided by pharmacokinetic evidence. Our post-approval study aimed to describe pharmacokinetic variability of ETI plasma concentrations in 15 participants who were administered a standard or reduced dose. ETI were quantified by LC-MS/MS in plasma samples taken prior to the morning dose. Results showed non-significant differences for each compound regardless of dosing regimen and after dose equivalence normalization. The majority of participants in both dosing groups had concentrations expected to elicit clinical response to ETI therapy. These findings indicate that dose reduction may be a viable strategy to maintain clinical benefit while managing intolerance.</p></div>","PeriodicalId":20799,"journal":{"name":"Pulmonary pharmacology & therapeutics","volume":null,"pages":null},"PeriodicalIF":3.3000,"publicationDate":"2024-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Pharmacokinetic variability of CFTR modulators from standard and alternative regimens\",\"authors\":\"Natalie R. Rose,&nbsp;Ashritha R. Chalamalla,&nbsp;Bryan A. Garcia,&nbsp;Stefanie Krick,&nbsp;Jonathan Bergeron,&nbsp;Hossein Sadeghi,&nbsp;Dennis E. Schellhase,&nbsp;Kevin J. Ryan,&nbsp;Alexander E. Dowell,&nbsp;Edward P. Acosta,&nbsp;Jennifer S. Guimbellot\",\"doi\":\"10.1016/j.pupt.2024.102301\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Elexacaftor, tezacaftor, ivacaftor (ETI) is a CFTR modulator combination approved for use in ∼90 % of people with cystic fibrosis (pwCF) over 2 years old. While most pwCF tolerate this therapy well, some are intolerant to standard dosing, and others show little response. Clinical providers may adjust ETI dosing to combat these issues, but these adjustments are not well guided by pharmacokinetic evidence. Our post-approval study aimed to describe pharmacokinetic variability of ETI plasma concentrations in 15 participants who were administered a standard or reduced dose. ETI were quantified by LC-MS/MS in plasma samples taken prior to the morning dose. Results showed non-significant differences for each compound regardless of dosing regimen and after dose equivalence normalization. The majority of participants in both dosing groups had concentrations expected to elicit clinical response to ETI therapy. These findings indicate that dose reduction may be a viable strategy to maintain clinical benefit while managing intolerance.</p></div>\",\"PeriodicalId\":20799,\"journal\":{\"name\":\"Pulmonary pharmacology & therapeutics\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":3.3000,\"publicationDate\":\"2024-05-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pulmonary pharmacology & therapeutics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1094553924000178\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pulmonary pharmacology & therapeutics","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1094553924000178","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

摘要

Elexacaftor、tezacaftor、ivacaftor(ETI)是一种 CFTR 调节剂复方制剂,已被批准用于 90% 的 2 岁以上囊性纤维化患者(pwCF)。虽然大多数囊性纤维化患者都能很好地耐受这种疗法,但有些患者对标准剂量不耐受,还有些患者则反应甚微。临床医疗人员可能会调整 ETI 的剂量以解决这些问题,但这些调整并没有很好的药代动力学证据作为指导。我们的批准后研究旨在描述 15 名服用标准剂量或减量剂量的参与者体内 ETI 血浆浓度的药代动力学变异性。通过 LC-MS/MS 对早晨用药前采集的血浆样本中的 ETI 进行定量。结果显示,无论采用哪种给药方案,在剂量等效归一化后,每种化合物的差异均不显著。两个给药组的大多数参与者的血药浓度都能引起对 ETI 治疗的临床反应。这些研究结果表明,减少剂量可能是在控制不耐受的同时保持临床疗效的一种可行策略。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Pharmacokinetic variability of CFTR modulators from standard and alternative regimens

Elexacaftor, tezacaftor, ivacaftor (ETI) is a CFTR modulator combination approved for use in ∼90 % of people with cystic fibrosis (pwCF) over 2 years old. While most pwCF tolerate this therapy well, some are intolerant to standard dosing, and others show little response. Clinical providers may adjust ETI dosing to combat these issues, but these adjustments are not well guided by pharmacokinetic evidence. Our post-approval study aimed to describe pharmacokinetic variability of ETI plasma concentrations in 15 participants who were administered a standard or reduced dose. ETI were quantified by LC-MS/MS in plasma samples taken prior to the morning dose. Results showed non-significant differences for each compound regardless of dosing regimen and after dose equivalence normalization. The majority of participants in both dosing groups had concentrations expected to elicit clinical response to ETI therapy. These findings indicate that dose reduction may be a viable strategy to maintain clinical benefit while managing intolerance.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
6.20
自引率
0.00%
发文量
41
审稿时长
42 days
期刊介绍: Pulmonary Pharmacology and Therapeutics (formerly Pulmonary Pharmacology) is concerned with lung pharmacology from molecular to clinical aspects. The subject matter encompasses the major diseases of the lung including asthma, cystic fibrosis, pulmonary circulation, ARDS, carcinoma, bronchitis, emphysema and drug delivery. Laboratory and clinical research on man and animals will be considered including studies related to chemotherapy of cancer, tuberculosis and infection. In addition to original research papers the journal will include review articles and book reviews. Research Areas Include: • All major diseases of the lung • Physiology • Pathology • Drug delivery • Metabolism • Pulmonary Toxicology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信